pharmaphorum

OCTOBER 27, 2021

AIT involves the administration of controlled, low doses of allergens under the tongue or by subcutaneous injection in people with allergies, with the aim of desensitising the immune system to them and prevent allergic reactions. ” The post Allergy specialist Stallergenes taps Aptar for digital delivery appeared first on.

Allergies 64

Allergies Drug Delivery Development Marketing 64

XTalks

JANUARY 17, 2023

While albuterol rescue inhalers are currently used to alleviate symptoms of an asthma attack, they don’t treat underlying inflammation, explained Bradley Chipps, MD, former president of the American College of Allergy, Asthma and Immunology, in a statement issued by AstraZeneca.

FDA Approval 97

FDA Approval Containment Allergies Drugs 97

Roots Analysis

MARCH 16, 2023

In the last few years, researchers have become interested in using in vitro transcribed (IVT) mRNA as a drug delivery agent. Furthermore, these drug candidates can be used to develop precise and individualized therapies that allow patients to produce therapeutic proteins in their own bodies.

Vaccination 52

Vaccination Vaccine DNA Protein 52

The Pharma Data

OCTOBER 14, 2020

15, 2020 /PRNewswire/ — Seattle Gummy Company’s breakthrough gummy drug program, which delivers Active Pharmaceutical Ingredients (APIs) in its innovative gummy matrix, recently won its first Investigational New Drug Application (IND) approval from FDA on the company’s allergy gummy medication, designated as IND 140312.

Drugs 40

Drugs Allergies Cardiology Medicine 40

The Pharma Data

SEPTEMBER 2, 2021

As a global leader in respiratory and allergy, we remain committed to reimagining medicine for patients living with chronic respiratory diseases like asthma.”. The sensor does not alter the drug delivery characteristics of the Breezhaler inhaler itself but produces a recording of each administered dose.

Licensing 52

Licensing Licensing Drug Delivery Allergies 52

XTalks

NOVEMBER 5, 2024

Trading began on the Nasdaq Capital Market under the ticker “PLRZ” on October 29, 2024. Its lead candidate, PL-14, targets nasal allergies and is scheduled for US Food and Drug Administration (FDA) submission via the 510(k) pathway, with preclinical trials expected to start in the second quarter of 2025 and pivotal trials by the end of 2025.

Drug Delivery 111

Drug Delivery Drugs Immune Response Allergies 111